<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710017</url>
  </required_header>
  <id_info>
    <org_study_id>TA-DMPA</org_study_id>
    <nct_id>NCT04710017</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid and Depot-Medroxyprogesterone Acetate for Perimenopausal Irregular Uterine Bleeding</brief_title>
  <official_title>Tranexamic Acid Versus Depot-Medroxyprogesterone Acetate in the Treatment of Perimenopausal Irregular Uterine Bleeding: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abnormal uterine bleeding is a symptom and not a disease. It is one of the most frequently&#xD;
      encountered complaints in gynecologic practice. It accounts for more than 70% of all&#xD;
      gynecological consultations in the peri- and post-menopausal age group.&#xD;
&#xD;
      Abnormal uterine bleeding may be acute or chronic and is defined as bleeding from the uterine&#xD;
      corpus that is abnormal in regularity, volume, frequency, or duration and occurs in the&#xD;
      absence of pregnancy.&#xD;
&#xD;
      Chronic heavy or prolonged uterine bleeding can result in anemia, interfere with daily&#xD;
      activities. Iron deficiency anemia develops in 21 to 67 percent of cases and raises concerns&#xD;
      about uterine cancer.&#xD;
&#xD;
      According to the International Federation of Obstetrics and Gynecology, the classification of&#xD;
      abnormal uterine bleeding is based on PALM-COEIN which is an acronym for various etiologies&#xD;
      namely polyp, adenomyosis, leiomyoma, malignancy and hyperplasia, coagulopathy, ovulatory&#xD;
      dysfunction, endometrial disorders, iatrogenic and not otherwise classified (PALM-COEIN).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of bleeding days</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Uterine Bleeding</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>will tranexamic acid 500 mg 4 times daily in one group,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medroxyprogesterone acetate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>will receive 150mg of medroxyprogesterone acetate once intramuscular.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>will be given Tranexamic acid at 500 mg four times daily (2 g/day) during the bleeding episodes for 5 days. The dose is 250 mg.</description>
    <arm_group_label>Tranexamic acid group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medroxyprogesterone Acetate 150 MG/ML</intervention_name>
    <description>will be given MPA at 150 mg once intramuscular injection</description>
    <arm_group_label>Medroxyprogesterone acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed, clinically as peri-menopausal abnormal uterine bleeding with&#xD;
             normal pelvic examination.&#xD;
&#xD;
          -  Patient's age ranging from 40- 55y.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Post menopausal women&#xD;
&#xD;
          -  Presence of fibroids, adenomyosis, polyp, adnexal mass, endometrial hyperplasia with&#xD;
             atypia, and breast malignancy).&#xD;
&#xD;
          -  Patients with uncontrolled hypertension.&#xD;
&#xD;
          -  Patient of abnormal bleeding profile.&#xD;
&#xD;
          -  history of liver impairment and renal insufficiency&#xD;
&#xD;
          -  Patients seeking for surgical management.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Women Health Hospital - Assiut university</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed K ALi, MD</last_name>
      <phone>+201005537951</phone>
      <email>m_khairy2001@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohammed Khairy Ali</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

